NCT04956744 - A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL

IMS001

IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).

Trial Locations (3)

RECRUITING

Shepherd Center, Atlanta

RECRUITING

Rocky Mountain MS Clinic, Salt Lake City

RECRUITING

UMass Memorial Medical Center, Worcester